Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Position Decreased by Geode Capital Management LLC

Geode Capital Management LLC decreased its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,924,773 shares of the company’s stock after selling 85,030 shares during the quarter. Geode Capital Management LLC owned about 2.28% of Atea Pharmaceuticals worth $6,449,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. BML Capital Management LLC increased its position in Atea Pharmaceuticals by 4.3% during the third quarter. BML Capital Management LLC now owns 6,650,000 shares of the company’s stock worth $22,278,000 after buying an additional 274,379 shares during the last quarter. FMR LLC boosted its stake in shares of Atea Pharmaceuticals by 2.8% during the 3rd quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after acquiring an additional 182,174 shares in the last quarter. State Street Corp increased its holdings in shares of Atea Pharmaceuticals by 0.7% during the 3rd quarter. State Street Corp now owns 1,733,486 shares of the company’s stock valued at $5,807,000 after acquiring an additional 11,566 shares during the last quarter. Almitas Capital LLC bought a new position in shares of Atea Pharmaceuticals in the 2nd quarter valued at approximately $4,271,000. Finally, Renaissance Technologies LLC raised its stake in shares of Atea Pharmaceuticals by 1.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,141,500 shares of the company’s stock valued at $3,778,000 after acquiring an additional 18,100 shares in the last quarter. Institutional investors and hedge funds own 86.67% of the company’s stock.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares in the company, valued at approximately $1,287,906.45. This represents a 44.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Stock Up 2.9 %

NASDAQ:AVIR opened at $3.52 on Friday. The company’s 50 day moving average is $3.27 and its 200-day moving average is $3.47. Atea Pharmaceuticals, Inc. has a 12 month low of $2.75 and a 12 month high of $4.60. The firm has a market cap of $297.31 million, a price-to-earnings ratio of -1.70 and a beta of 0.20.

Atea Pharmaceuticals (NASDAQ:AVIR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.13. During the same period last year, the firm posted ($0.40) EPS. Research analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.